Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combined medicine having efficacy of antineoplastic drugs

An anti-tumor drug and drug technology, applied in the direction of anti-tumor drugs, medical preparations containing active ingredients, drug combinations, etc., can solve unseen problems, achieve low toxicity, alleviate hematopoietic function damage, and relieve weight loss Effect

Active Publication Date: 2017-12-22
SICHUAN JIUZHANG BIO TECH CO LTD
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] There is no report on the combined use of pemetrexed and other dihydrofolate reductase inhibitors with chlorogenic acid

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combined medicine having efficacy of antineoplastic drugs
  • Combined medicine having efficacy of antineoplastic drugs
  • Combined medicine having efficacy of antineoplastic drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] The in vitro test of embodiment 1 combined drug

[0022] 1. Experimental materials

[0023] Reagents: chlorogenic acid, pemetrexed, aminopterin.

[0024] Cell lines: lung adenocarcinoma A549 cell line, breast cancer MCF-7 cell line, liver cancer BEL-7402 cell line.

[0025] 2. Test method

[0026] 2.1 Cell Recovery

[0027] Take out the frozen cell line from the ultra-low temperature freezer at -152°C, thaw it in a water bath at 40°C, centrifuge and wash with basal medium, suspend the cells with culture medium, transfer to a cell culture bottle, and place it in a 5% CO2 cell culture incubator for 37 Cultivate at ℃, change the medium every 2-3 days. After the cells grew to cover the cell bottle, they were digested with 0.25% trypsin and subcultured to the number of cells required for the experiment.

[0028] 2.2 Dosing culture

[0029] Take the cells in logarithmic growth phase, digest with 0.25% trypsin, wash and centrifuge with basal medium (1000rpm 5min twice), ...

Embodiment 2

[0062] Anti-tumor animal experiment of embodiment 2 drug combination

[0063] 1. Experimental materials

[0064] Reagents: chlorogenic acid, pemetrexed, aminopterate, methotrexate

[0065] Animals: BALB / C-nu mice (SPF grade, body weight: 16-21 g, female).

[0066] Cell lines: Lewis mouse lung cancer cell line, H22 mouse liver cancer cell line, EMT-6 mouse breast cancer cell line

[0067] 2. Test method

[0068] 2.1 Method

[0069] Take the cells in the logarithmic growth phase, digest them with trypsin until they are detached, and then add physiological saline to make a cell suspension. -1 (approximately 1×10 cells 6 1), inoculated under the left anterior armpit of the mice, and randomly divided them into chlorogenic acid group, pemetrexed group, aminoptrexate group, methotrexate, chlorogenic acid+pemetrexed combined drug group, chlorogenic acid + aminopterate, chlorogenic acid + methotrexate combined drug group, and negative group, 6 rats in each group, administered int...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a combined medicine having efficacy of antineoplastic drugs. The combined medicine consists of chlorogenic acid and a dihydrofolate reductase inhibitor of unit preparations in same or different specifications, and a pharmaceutically acceptable carrier, wherein the chlorogenic acid and the dihydrofolate reductase inhibitor are applied in a simultaneous or separated mode. According to the combined medicine, a synergistic effect can be developed when the chlorogenic acid and the DHFR (dihydrofolate reductase) inhibitor are used in a combined mode, and hematopoietic function injury and weight loss caused by the DHFR inhibitor can be relieved; toxic and side effects of the DHFR inhibitor can be effectively reduced; and the medicine, which combines the chlorogenic acid and the DHFR inhibitor is excellent in curative effect, low in toxicity and good in prospect of clinical application.

Description

technical field [0001] The invention relates to a combination drug with antitumor drug effect. Background technique [0002] Dihydrofolate reductase (DHFR) is a very important enzyme in organisms, which catalyzes the reduction of dihydrofolate to tetrahydrofolate in organisms, and provides one-carbon for the process of biosynthesizing DNA precursor thymidine unit. In the process of tumor cell growth, DHFR inhibitors can selectively combine with DHFR, inhibit its catalytic reduction activity, prevent dihydrofolate from being transformed into tetrahydrofolate, interfere with the synthesis of DNA and protein, and eventually lead to cell death, thereby achieving anti-inflammatory effects. tumor purpose. [0003] DHFR inhibitors have obvious anti-tumor effects and are often used as first-line and second-line treatments. However, because they are cytotoxic drugs, they cause great damage to the body and cannot be treated continuously. In order to reduce the toxic and side effect...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/216A61K31/519A61P35/00A61P35/02
CPCA61K31/216A61K31/519A61K2300/00
Inventor 张洁黄望杨华蓉
Owner SICHUAN JIUZHANG BIO TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com